NCT03180710 - A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 6, 2017

Primary Completion Date

August 28, 2017

Study Completion Date

December 21, 2017

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

BioChaperone® Combo 75/25 at 0.6 U/kg

Injection of BioChaperone® Combo 75/25 at 0.6 U/kg

DRUG

BioChaperone® Combo 75/25 at 0.8 U/kg

Injection of BioChaperone® Combo 75/25 at 0.8 U/kg

DRUG

BioChaperone® Combo 75/25 at 1.0 U/kg

Injection of BioChaperone® Combo 75/25 at 1.0 U/kg

DRUG

Humalog® Mix25 at 0.8 U/kg

Injection of Humalog® Mix25 at 0.8 U/kg

Trial Locations (2)

Profil Mainz GmbH & Co. KG, Mainz

Profil Institut für Stoffwechselforschung GmbH, Neuss